harmila Joshi of sharmilajoshi.com told CNBC-TV18, "One should definitely hold Jubilant Life Sciences and I think within the pharmaceutical space there are a few names that have sort of withstood this whole onslaught of inspections, etc. and maybe because the business models are also different. So, I would say one of those companies has been Jubilant Life Sciences. So, from my side it is a definite hold with a long-term view."
Jubilant Life Sciences ended at Rs 822.30, up Rs 73.60, or 9.83 percent.It has touched a 52-week high of Rs 829.35 on the BSE.